Following the success obtained with transplantation of fresh human islets under steroid-free immunosuppression, this trial evaluated the transplantation of islets that had undergone a period of in vitro culture and the potential of tumor necrosis factor (TNF-a) blockade to improve islet engraftment. Subjects included 16 patients with type 1 diabetes mellitus (T1DM); half were randomly assigned to receive Infliximab immediately preceding initial infusion. Immunosuppression consisted of daclizumab induction and sirolimus/tacrolimus maintenance. Out of 16 subjects 14 achieved insulin independence with one or two islet infusions; adverse events precluded completion in two. Without supplemental infusions, 11/14 (79%) subjects were insulin independent at 1 year, 6/14 (43%) at 18 months; these same subjects remain insulin independent at 33 ± 6 months. While on immunosuppression, all patients maintained graft function. Out of 14 patients, 8 suffered chronic partial graft loss, likely immunological in nature, 5 of these received supplemental infusions. Currently, 11 subjects remain on immunosuppression, 8 (73%) are insulin independent, two with supplemental infusions. Insulin independent subjects demonstrated normalization of HbA1c, fructosamine and Mean Amplitude of Glycemic Excursions (MAGE) values. No clinical benefit of infliximab was identified. These results demonstrate that transplantation of cultured human islet allografts results in reproducible insulin independence in all subjects under this immunosuppressive regimen, comparable to that of freshly transplanted islets (Edmonton protocol).
Introduction
One of the most promising new interventions for patients suffering with type 1 diabetes mellitus (T1DM) is islet transplantation (1, 2) . High rates of insulin independence in the short term have been reproduced at this (3) and other centers (4) (5) (6) (7) (8) , since the initial announcement of 100% insulin independence from the center in Edmonton in 2000 (1) . Results at 2-and 3-year post-transplant remain promising (9, 10) , and the existence of several subjects with continued islet allograft survival is allowing for evaluation of the long-term safety and efficacy of this new therapy.
Islet culture offers several advantages ranging from ensuring the quality of islet preparations (11) to possibly decreasing immunogenicity of the allograft tissue (12) while also allowing additional time for subject preparation, possible pre-transplant interventions and the opportunity to ship processed islets to remote sites for transplantation (13) .
Persistent limitations include the need for multiple donor pancreata to achieve insulin independence (1) (2) (3) (4) (5) (6) (7) and lower rates of insulin independence in the long term (2) (3) (4) 7, (9) (10) . This study sought to address these issues through maximizing islet yield at isolation, ensuring the quality of islet preparations through culture and enhancing islet engraftment using cytokine blockade. The possible causes of long-term graft dysfunction and the use of supplemental infusions to restore insulin independence were also evaluated.
Methods
Sixteen patients with T1DM and hypoglycemia unawareness were enrolled in this single-center, prospective, randomized trial of islet transplantation. Patients with renal dysfunction (serum creatinine >1.6 mg/dL or macroalbuminuria) were ineligible. The protocol was approved by the University of Miami health research ethics board (IRB) and each subject gave written informed consent.
Immunosuppression, started on post-operative day (POD)−1, consisted of maintenance with tacrolimus (Prograf ® , Fujisawa, Japan), target trough level 4-6 ng/mL and sirolimus (Rapamune ® , Wyeth Pharmaceuticals, Inc., Madison, NJ, USA), target trough level 12-15 ng/mL for 3 months, 10-12 ng/mL thereafter and a five-dose induction course of daclizumab (Zenapax ® , Roche, Nutley, NJ, USA), 1 mg/kg biweekly beginning the day of transplant. Due to concern of graft dysfunction following reappearance of CD25+ cells in the peripheral blood, daclizumab infusions were continued monthly and bimonthly for the first and second years post-transplant, respectively. Half of the subjects were randomized to receive a single dose of infliximab (Remicade ® , Centocor, Malvera, PA, USA) 5 mg/kg 2 h prior to their first infusion. The final three subjects received 10 mg/kg due to emerging data suggesting that 5 mg/kg was not sufficient to abrogate tumor necrosis factor (TNF-a) elevation.
Live, multiorgan cadaveric donors, 15-65 years of age, with <10 minutes warm ischemia time, were the source of pancreata. Harvested organs were preserved using standard ice slurry UW (University of Wisconsin) solution or the two-layer method (TLM)-UW/perfluorocarbon (PFC) (8, (14) (15) (16) . Organs arriving in UW solution only were placed in PFC for 4-6 h, up to a total of 20 h cold ischemia prior to islet isolation.
Islets were isolated using a modified automated method (17) and purified using continuous gradients (ficoll/biocoll); repurification of unsatisfactory separations was attempted using discontinuous (ficoll/eurocollins) gradients (rescue) (18) . Isolated islets were cultured in Miami defined media with 95% air and 5% carbon dioxide (CO 2 ) at 37
• C for 24 h and 22
• C thereafter, up to a total of 72 h (19, 20) . Following culture islets underwent standard product release testing (5, 21) . For infusion, islets were resuspended as previously described (22) .
Islets were transplanted via the percutaneous transhepatic intraportal route, using ultrasound guidance for portal vein puncture and infused using the bag infusion technique (22) , with close monitoring of portal venous pressure (PVP). Recently, the procedure was modified to use D-Stat TM (Vascular Solutions, MN) for tract closure (23) .
Graft function was monitored using fingerstick glucose (FSG), basal cpeptide, HbA1c, fructosamine and stimulation testing. Those subjects who were insulin independent with an HbA1c within the normal range were considered to have a complete reversal of diabetes. Graft dysfunction, defined as more than three fasting FSG >140 mg/dL and/or 2h postprandial FSG >180 in a single week, merited reintroduction of exogenous insulin. Subjects maintaining euglycemia and normal HbA1c on a reduced dose of exogenous insulin, with stimulated C-peptide >0.5 ng/mL, were considered transplant improved and were eligible for a supplemental infusion.
Stimulation tests, including response to intravenous glucose (IVGTT), arginine and mixed meal tolerance test (MMTT), were performed quarterly for 18 months, then every 6 months. Subjects who remained insulin independent with fasting FSG <126 mg/dL, underwent oral glucose tolerance testing (OGTT) annually. Acute insulin release to glucose (AIRg), arginine (AIRarg) and sustacal stimulation index (SSI) were calculated as previously described (24) .
Immunological monitoring included cytotoxic lymphocyte gene (CLG) expression in peripheral blood and MLC as previously described (25) , phenotyping (including CD25+ cells), autoantibody levels (GAD65, IAA), PRA and CMV serology.
Adverse events were assessed regularly post-transplant and categorized using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.
The results are expressed as mean ± SD. The results before and after transplant are compared using analysis of variance and Kaplan-Meier survival analysis (Winstat ® for Excel, Columbus, OH, USA).
Results
Subjects (Table 1) included seven males and nine females, six of whom were using an insulin pump. All subjects had hypoglycemia unawareness; glycemic control was suboptimal in the majority (HbA1c > 7.5% in 10/16 subjects).
Forty donor organs were utilized for 34 infusions (first, second and supplemental) in 16 subjects; five infusions combined multiple donors (two donors: n = 4; three donors: n = 1). A transient rise in liver transaminases was noted, temporally related to each islet infusion, onset 4-5 days posttransplant and resolution by 2-3 weeks; unrelated to TTV or peak PVP. In and out of phase MRI imaging performed annually demonstrated diffuse punctate parenchymal lesions in 1/13 subjects evaluated, consistent with peri-islet fatty infiltration (Figure 1 ). This subject had reintroduced exogenous insulin 14 days earlier.
Insulin independence was achieved in 14 of 14 subjects after one (n = 1) or two (n = 13) infusions. Two subjects were unable to undergo a second islet infusion due to serious adverse events (SAE) requiring cessation of immunosuppression; aspiration pneumonia of unknown etiology (n = 1) and parvovirus-induced anemia (n = 1).
To achieve insulin independence, a mean of 934 280 ± 209 252 IEQ (13 552 ± 2982 IEQ/kg) were infused. Only one subject achieved insulin independence with a single infusion of 606 284 IEQ (6250 IEQ/kg) and remains so at almost 3 years post-transplant (Table 2) . At 1 month following first infusion, insulin requirements were reduced by a mean of 56 ± 19% (n = 16), insulin was discontinued immediately following the second infusion ( Figure 2 ). Four subjects received combined infusions for first (n = 2) or second (n = 2) infusions, three remained insulin independent at >2.5 years, one reintroduced insulin on POD 357. One supplemental infusion utilized a combined preparation, insulin independence persists at POD 382.
The use of infliximab 5 or 10 mg immediately before islet infusion, did not translate to a demonstrable clinical benefit.
Similarly, the need for a second infusion and response to various metabolic stimuli were not affected (see Table 3 ).
Six months following initial infusions, all subjects had complete reversal of diabetes. Without supplemental infusions, insulin independence was sustained in 11 of 14 (79%) at 1 year and 6 of 14 (43%) at 18 months; these same subjects remain insulin independent at a mean of 33 ± 6 months. While on immunosuppression, all subjects remain(ed) cpeptide positive (100%), i.e. complete graft loss was not encountered (Figure 3 ).
Insulin independence and stable graft function resulted in fasting serum glucose levels that were normal (<100 mg/dL) in five subjects, and impaired in the remaining nine (100 < X < 126 mg/dL) (see Figure 4 ) (26) . Despite the wide range of fasting serum glucose values, there was normalization of MAGE, HbA1c and fructosamine. Continuous glucose monitoring was comparable with normal controls (typical profile is shown in Figure 5B ). Basal c-peptide and insulin levels at 3 months post-insulin independence were 1.4 ± 0.4 ng/mL (range: 0.7-2.1) and 7.16 ± 5.1 lU/mL (range: 3.0-20.1), respectively. High insulin levels were due to insulin antibodies in one subject.
Insulin Reduction with Islet Infusion (s)
At 3 months post-achievement of insulin independence, stimulation using MMTT provided maximal C-peptide response from basal 1.61 ± 0.67 to peak 3.45 ± 0.66 (n = 14); SSI at the same time point was 0.73 ± 0.21, which is approximately half of that seen in normal controls (24) . AIRg was also approximately half that of normal controls (19.73 ± 10.62; n = 14), although first phase insulin release was preserved. A loss of first phase insulin release was associated with the need for reintroduction of insulin. IVGTT and MMTT showed a gradual decline over time, greater in patients that required a reintroduction of insulin (data not shown). OGTT evaluated at 1 year, was normal in 5 of 10 subjects; impaired in three and consistent with diabetes in two; it was essentially unchanged at 2 years ( Figure 5C ,D).
Exogenous insulin was restarted in 8 of 14 subjects at POD 381 ± 111 (range: 208-513) ( Table 2 ). FSG elevation was the first clinical indicator of graft dysfunction with acute (n = 4) or subacute (n = 4) deterioration characterized by fasting and post-prandial hyperglycemia developing over 24-48 h in the former and over weeks to months, not immediately requiring reintroduction of insulin in the latter. Deterioration in glycemic control was usually associated with a concomitant decrease in the c-peptide/glucose ratio (ratio reduction 0.52 ± 0.2, n = 8 compared with stable patients 0.002 ± 0.29, n = 6, p = 0.002). Total daily dose of insulin was 12.6 ± 5.4 U compared with 32.7 ± 11.2 U pre-transplant, a reduction of 59 ± 18%, and was delivered as long-acting insulin (Lantus); no pre-meal short-acting insulin was required to maintain near-normal glycemic control with persistent absence of severe hypoglycemia.
Of the eight subjects who restarted insulin, five received a supplemental infusion, which restored insulin independence immediately in two and delayed in one (POD 81) ( Table 4 ). The fourth had no demonstrable change in insulin requirements, stabilizing at pre-infusion requirement of 10 U Lantus daily on POD 109. Insulin independence was achieved for 113 days with the adjunct of pioglitazone (Actos ® , Takeda Chemical Industries Ltd., Osaka, Japan); however, the medication was not tolerated and euglycemia was maintained through reintroduction of 10 U Lantus daily. The final subject never achieved insulin independence likely due to high pre-infusion insulin requirements and/or unstable graft function due to ongoing immunemediated events (25) . One insulin independent subject, required reintroduction of insulin again at 303 days postsupplemental infusion and remains euglycemic on Lantus 8-10 U daily. Supplemental infusions were precluded in three subjects (Hypereosinophilic syndrome (HES) n = 1, lost to follow-up n = 1, voluntary withdrawal n = 1).
At a mean follow-up of 33 ± 6 months, eleven subjects remain on immunosuppression, eight of whom are insulin independent (73%), two of these with supplemental infusions. Three subjects require a mean of 21.3 U/day (range: 8-44), decreased from 51.5 U/day, (range: 39-66), a 62% mean reduction.
During post-transplant follow-up, analysis of mRNA levels for cytotoxic lymphocyte genes (CLG) in the peripheral blood, demonstrated peak elevations weeks to months prior to loss of graft function and are indicative of immunemediated graft loss (25) . This is further supported by the finding of sensitization by MLC to one or more of the donors. These findings are similar to those we have published in nonhuman primate islet allograft recipients (27) .
PRA (cytotoxic) levels have remained below 5% in all subjects in the post-transplant period, confirming the absence of humoral sensitization at this time, despite presumed partial rejection in some subjects.
Extended post-transplant administration of daclizumab over 2 years successfully eliminated CD25+ cells from the peripheral blood without adverse effects. Reappearance of CD25+ cells occurred at 119 ± 19.2 days (n = 7) following last daclizumab infusion. Out of 14 subjects, 5 had a break in coverage (range: 119-167 days), CD25+ cells reappeared in four of these, two developed graft dysfunction at 41 and 161 after reappearance of CD25+ cells, two remained insulin independent. The fifth subject developed dysfunction without CD25+ cells. Nine subjects received continuous coverage for 2 years, five developed graft dysfunction in the absence of CD25+ cells.
Autoantibody data demonstrated nine subjects were positive pre-transplant, (GAD65 n = 6, IA2 n = 1, both n = 2). Two subjects became IA2 positive post-transplant, one withdrew at POD 102 (unrelated), the second remains insulin independent at POD 661. Two subjects became GAD65 positive post-transplant, both reintroduced insulin, both underwent successful supplemental infusions; one remains insulin independent, the other reintroduced insulin again at POD 303. No patient became negative for either antibody. Two subjects had extremely high levels of IA2 antibody pre-and post-transplant, one remains insulin independent at POD 1130, the second (also converted to GAD65 positive) suffered partial graft loss, received a supplemental infusion and is currently insulin independent at POD 1024. There was no significant difference in time to onset of graft dysfunction when comparing pre-transplant autoantibody status, high levels of autoantibodies, presence of 0, 1 or 2 autoantibodies or seroconversion.
SAEs requiring cessation of immunosuppression (n = 3) included aspiration pneumonia, parvovirus infection and HES (28) . Other SAEs requiring removal of tacrolimus (n = 4) included short-term memory loss, renal dysfunction, eczema and insomnia/depression. Grade 4 (National Cancer Institute criteria) leucopenia/neutropenia occurred in nine patients, requiring granulocyte colony-stimulatingfactor treatment in five.
Two subjects demonstrated a rise in serum creatinine from baseline compared with most recent values (0.67 ± 0.25:1.3 ± 0.07 and 0.98 ± 0.17:1.51 ± 0.21), there was no appreciable change in corrected creatinine clearance measured using 24-h urine collection. Five subjects developed macroalbuminuria at mean 14 ± 9 months post-transplant. All subjects developed proteinuria; onset of >150 mg/24 h was at a mean of 15 ± 10 months post-transplant (range: 1.2-37). In the majority, onset was abrupt and progressive over time. Five subjects experienced levels >500 mg per 24 h, these included those with progressive macroalbuminuria and serum creatinine elevation. Mild hypertension developed in one subject.
New onset or exacerbation of hyperlipidemia was noted in 14 of 16 subjects requiring introduction or increase in lipid lowering medication. There was no significant triglyceride elevation in any subject. Other common side effects included mouth ulcers and peripheral edema which are likely sirolimus related; insomnia, tremor, anxiety and headaches likely tacrolimus related; gynecological abnormalities (29), bone marrow suppression, electrolyte abnormalities and proteinuria likely related to immunosuppression in general. These events were generally self-limiting or responded to treatment. Until recently, no opportunistic infections or CMV disease occurred in any subjects despite transplantation of islets from seropositive donors into seronegative subjects in 10 cases (30) . One subject, however, has recently seroconverted for CMV suggesting occurrence of subclinical disease.
Discussion
In the short term, islet transplantation is a highly successful treatment for subjects with T1DM resulting in insulin independence provided immunosuppression is tolerated and sufficient islets are transplanted, similar to results in other centers (1, (4) (5) (6) (7) (8) . Medium-term follow-up of these subjects demonstrates continued islet function (c-peptide positivity), but a loss of insulin independence in the majority of subjects over 3-4 years.
Multiple factors contribute to achieving this success and attention to detail is critical at all phases of the sequential, multidisciplinary approach for effective islet transplantation. This begins with maximizing the number of suitable donor organs through careful procurement (31, 32) and transportation using the TLM (8, (14) (15) (16) . Following isolation, a period of culture allows for better product characterization (11), identification of late-appearing poor preparations while providing time for patient preparation and islet transportation to distant centers. Culture consistently decreased TTV, of benefit in minimizing procedure-related complications and reducing the amount of tissue embolized into the liver, while the concomitant decrease in IEQ maybe in part due to a reduction in islet swelling. It is conceivable that the destiny of surviving and dying islets following isolation is already predetermined and culture merely differentiates these and provides time and optimal conditions for surviving islets to recover from the trauma of isolation, thereby perhaps also resulting in purer/healthier preparations.
Combining preparations was minimized to avoid exposure to multiple donors, but was equally effective in achieving insulin independence. Since immunological loss of islets may be donor specific, having multiple donors may be of benefit in maintaining some graft function although this must be balanced with the risk of sensitization to multiple alloantigens.
Even with the best preparations, however, the number of IEQ required to achieve insulin independence is high compared to autotransplantation (33) , and are at least as many if not more than in the normal pancreas. This supports the concept that large losses occur at the time of transplantation when islets are believed to be most vulnerable (34) (35) (36) . The use of Infliximab in an attempt to improve engraftment did not translate to a demonstrable clinical benefit, whether higher dosages or longer duration of treatment would uncover a beneficial effect could not be discerned. TNF-a is one cytokine, which has been shown to be detrimental to engrafting islets (37, 38) ; however, blockade of a single cytokine may not be sufficient to survive the storm.
Functioning intrahepatic islets can normalize most diabetic parameters although fasting glucose values are consistent with impaired fasting glucose in the many subjects.
Marginal islet mass, as suggested by stimulation testing, may be responsible for this, although other etiologies such as drug-induced increased peripheral resistance (39), abnormal islet physiology and/or secreted insulin bypassing the liver may also contribute. The absence of severe hypoglycemia characterizes the most dramatic and clinically relevant shift in diabetic control.
An elevation of fasting and/or post-prandial FSG levels was the first clinical sign of graft dysfunction in all subjects. Despite reintroduction of insulin, control was maintained with a single injection of long-acting insulin (Lantus), no premeal short-acting insulin was required and hypoglycemia was still averted.
The potential causes of graft loss include rejection, recurrent autoimmunity or cell death from hostile environment, drug toxicity and hyperglycemia. Concern that the reappearance of activated T cells was the cause of graft loss resulted in prolonged daclizumab administration, which did not appear to confer any clinical advantage. The removal of existing CD25+ cells at induction may assist engraftment, their reappearance during maintenance phase however, may not be detrimental to graft function; in fact, it has been hypothesized that the presence of CD25+ cell subsets (regulatory T cells) may be beneficial to graft survival through immune regulation (40, 41) .
Immunosuppression had no effect on autoantibody levels in the majority of subjects. Presence, absence, appearance, or high levels of autoantibodies did not correlate with graft dysfunction, although the gradual/delayed loss of function as seen in whole organ transplantation suggestive of recurrent autoimmunity may not yet be apparent (42) .
A novel approach was the measurement of CLG at regular intervals post-transplant, which demonstrated elevations that preceded clinical graft dysfunction (25) . This suggests immunologically mediated graft loss corroborated by reappearance of donor-specific sensitivity (MLC) despite no change in PRA levels. Because of the long interval between elevation and clinical changes and the often gradual clinical deterioration leaves some question as to the exact nature of this 'rejection', while not excluding multifactorial causes.
Calcineurin inhibitors have well recognized b-cell toxicity (43) (44) (45) , which may contribute to graft dysfunction. Two subjects demonstrated an improvement in glycemic control following substitution of tacrolimus with MMF. Of note, the potentially negative effects of these drugs may be amplified by the intrahepatic site of the islet grafts, since portal levels of these agents are significantly higher compared to systemic levels (46) .
Evaluation for predictors of success did not identify any single indicator. In a setting where an immunological event can occur at any time and has occurred in the majority of subjects the ability to evaluate such an indicator is limited. The infrequency of stimulation testing makes it an untimely instrument for predicting acute graft dysfunction. Loss of first phase insulin release during IVGTT and decrease in peak c-peptide during MMTT was seen in all patients with graft dysfunction and is similar to the findings in the prediabetic prior to the emergence of insulin requiring frank hyperglycemia-a portend of the failing islet? The significance of a marginal mass as demonstrated by stimulation testing results is not known, this may be sufficient in and of itself to cause gradual loss of islet mass through cell exhaustion.
Supplemental infusions, while successful in re-establishing insulin independence in most subjects, do not appear as effective as initial infusions. Additionally, achieving the immunosuppression levels required for engraftment was more difficult and resulted in adverse events of greater frequency and severity. Currently, such procedures are limited to subjects who have stable insulin requirements over 3 months and achieve euglycemia with a total daily dose of less than 20 U insulin. Since loss of function is believed secondary to selective rejection of one or more of previous donors (25) , supplemental infusions should be mismatched with 'rejected' donors.
The percutaneous transhepatic approach remains the preferred approach for islet transplantation. Major complica- tion rate is low; hemorrhage, when it does occur, is typically from the catheter tract and procedure modification to use D-stat TM (23) for complete tract obliteration maybe sufficient to prevent this. PVP rises in most infusions, greater with TTV > 3 cc. Unlike the Edmonton experience (47), there was no significant change in PVP rise/cc TTV with sequential infusions (Table 5 ). To date, no subject has experienced portal vein thrombosis. This may be due to lower TTV and lower acinar component of the preparations secondary to islet culture and the bag infusion technique (22) .
Sirolimus and tacrolimus are highly efficacious in maintaining function; however, the toxicity of this regimen is still being defined. Noncompletion and withdrawal of subjects secondary to SAE's was unlikely related to these specific immunosuppressive agents. In the short term tacrolimus was less well tolerated due to symptomatic side effects. Tacrolimus and sirolimus appear to have a synergistic effect, which may explain why significant side effects of tacrolimus are noted even at the low levels used in this regimen. The alterations in renal function are of particular concern and while tacrolimus has well recognized nephrotoxicity more data are emerging to implicate sirolimus (52) . Concern exists regarding the longer term use of sirolimus due to its antiproliferative effect that could potentially impair the ability of islets cells to replicate during prolonged follow-up and the higher rates of sirolimus attributed side effects over time.
The long-term effect of islet transplantation on the liver is not known. The relatively new MRI observation consistent with focal peri-islet fatty infiltration (48-50) as demonstrated histologically and in primates (51) is of uncertain significance. At this institution its prevalence is too low to assess correlation with graft dysfunction.
In conclusion, islet transplantation in the short term can consistently and reliably reverse insulin dependency in subjects with 'severe' T1DM. While islet transplantation does not achieve perfect glycemic control in all subjects, resulting more commonly in impaired fasting glucose or postislet-transplant diabetes, this level of function results in normalization of all diabetic parameters and prevention of severe hypoglycemia even in subjects that require reintroduction of exogenous insulin. Long-term cryptic causes of graft dysfunction may be immunologically mediated with chronic drug toxicity and/or exhaustion contributing. The lack of more sensitive methods to predict graft loss and elucidate its mechanisms in order to preserve islet mass over time, the need for less toxic immunosuppressive regimens and reducing the number of islets required to reverse diabetes leave room for improvement to realize the full potential of this treatment.
